This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Apellis Pharmaceuticals Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Apellis Pharmaceuticals de 29.8% y 8.6% por año respectivamente. Se prevé que el BPA crezca en un 30.1% al año. Se espera que la rentabilidad financiera sea de 55.1% en 3 años.
Información clave
29.8%
Tasa de crecimiento de los beneficios
30.09%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 25.2% |
| Tasa de crecimiento de los ingresos | 8.6% |
| Rentabilidad financiera futura | 55.05% |
| Cobertura de analistas | Good |
| Última actualización | 15 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Apr 29
APLS: Biogen Deal Terms And Mixed Ratings Will Guide Future Repricing
Analysts have raised the fair value estimate for Apellis Pharmaceuticals to about $40.93, citing Street research that combines several recent price target increases with a series of downgrades following Biogen's acquisition announcement, along with updated views on long-term P/E assumptions and risk. Analyst Commentary Street research around the Biogen acquisition announcement shows a split in how analysts are framing Apellis Pharmaceuticals, with some highlighting upside to long-term value and others focusing on execution and pricing risks.Actualización de narrativa • Apr 15
APLS: Balanced Biogen Deal And Mixed Ratings Will Shape Future Repricing
Apellis Pharmaceuticals' updated fair value estimate has shifted from $35.71 to $39.93 per share as analysts factor in higher long run P/E assumptions near 42x, alongside recent price target changes that include several upgrades, downgrades and target raises from firms such as Mizuho, JPMorgan, Morgan Stanley and RBC Capital. Analyst Commentary Recent Street research on Apellis Pharmaceuticals shows a split tape, with several firms lifting price targets while a cluster of downgrades points to fresh execution and valuation questions.Actualización de narrativa • Apr 01
APLS: Syfovre Outlook And Downgrade Wave Will Limit Future Repricing
Analysts now see fair value for Apellis Pharmaceuticals at about $35.71 per share, up from roughly $33.60, reflecting updated views on revenue growth, margins, discount rates, and a somewhat higher future P/E multiple after a mix of recent price target raises, initiations, and downgrades across the Street. Analyst Commentary Street research on Apellis Pharmaceuticals reflects a mixed but engaged view, with both bullish and bearish analysts adjusting targets, ratings, and coverage in response to recent reports and product updates.Seeking Alpha • Mar 31
Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing
Summary Biogen acquires Apellis for $41/share, a 140% premium, aiming to leverage Apellis’ nephrology sales force and product portfolio. Syfovre’s safety issues have stabilized, but its commercial prospects remain limited versus Astellas’ Izervay, justifying Biogen’s cautious CVR structure. Biogen’s acquisition thesis hinges on felzartamab’s potential in complement-mediated rare diseases, especially AMR, targeting $800M+ peak sales. I downgrade APLS to 'Sell' post-acquisition, as upside is realized; BIIB remains a 'Hold' given execution risk and dependence on felzartamab’s success. Read the full article on Seeking AlphaActualización de narrativa • Mar 18
APLS: Kidney Disease Launch And Index Adds Will Drive Future Repricing
Narrative Update on Apellis Pharmaceuticals The updated analyst price target framework now aligns with Street research that has recently adjusted Apellis price objectives in a roughly $18 to $44 range, with analysts pointing to demand trends for Syfovre and Empaveli, mixed views on growth beyond the current Q4 reporting period, and differing assumptions for revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Apellis Pharmaceuticals presents a mixed picture, with price targets spanning roughly US$18 to US$44 and a range of views on execution, product demand and future growth.
Actualización de narrativa • Mar 04
APLS: Future C3G Launch Execution Will Drive Bullish Re Rating Potential
Apellis Pharmaceuticals' updated analyst price targets cluster around the high teens to mid $40s, with modest adjustments up and down as analysts factor in the Q4 update, expectations for flat Syfovre pricing into FY26, progress in the C3G launch, and slightly revised assumptions for growth, margins, and future P/E. Analyst Commentary Recent Street research on Apellis Pharmaceuticals reflects a mixed but generally constructive stance, with price targets spanning from the high teens into the mid $40s and a blend of Neutral, Buy, and Overweight views.Actualización de narrativa • Feb 17
APLS: Kidney Disease Launch And Index Adds Will Support Future Repricing
Analysts have nudged their consolidated price target and fair value framework for Apellis slightly higher to $33.95, reflecting a blend of cautious optimism from fresh Neutral initiations and upgrades, along with mixed target revisions following the recent Q4 pre-announcement and C3G launch commentary. Analyst Commentary Recent research has focused on how Apellis is executing around its Q4 pre announcement and the early C3G launch, and what that means for valuation and risk.Actualización de narrativa • Feb 03
APLS: Kidney Disease Launch And Index Additions Will Support Future Share Recovery
Analysts have trimmed their average price target on Apellis Pharmaceuticals by about US$1.44 per share, reflecting more cautious assumptions on revenue growth and profit margins, even as some recent research updates point to steady product launches and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on Apellis Pharmaceuticals shows a split view, with some analysts focusing on product execution and others emphasizing revenue uncertainty and guidance gaps.Actualización de narrativa • Jan 20
APLS: Future C3G Renal Uptake Will Drive Bullish Re Rating Potential
Analysts have slightly increased their overall price expectations for Apellis, with recent Street targets clustering in a US$27 to US$45 range, as they balance cautious views on Syfovre revenue trends and guidance gaps against ongoing uptake in C3G and related renal indications. Analyst Commentary Recent Street research shows a mix of caution and optimism on Apellis, with several bullish analysts highlighting areas where they see the story improving around execution, revenue mix and potential upside to current expectations.Actualización de narrativa • Jan 05
APLS: Future Renal Indication Execution Will Drive Bullish Re Rating Potential
Analysts have trimmed their price targets for Apellis Pharmaceuticals, with recent cuts to US$45 and US$27. These moves reflect concerns about "flattish" Syfovre revenue and uncertainty around Empaveli's early renal indications, even as long term fair value assumptions and projected revenue growth in some models remain unchanged.Actualización de narrativa • Dec 14
APLS: Future Kidney Indication Uptake Will Drive Bullish Re-Rating Potential
Analysts have trimmed their average price target on Apellis Pharmaceuticals by about $5 per share. They cite higher perceived risk, slower expected revenue growth from Syfovre and Empaveli, and somewhat lower long term margin assumptions, although several covering firms remain generally supportive.Actualización de narrativa • Nov 29
APLS: Kidney Disease Indication Launch Will Drive Share Price Recovery Ahead
Analysts have modestly lowered their average price target for Apellis Pharmaceuticals. They cite cautious outlooks on revenue growth and recent segment performance, with new targets ranging from $27 to $45 per share compared to prior targets up to $52.Actualización de narrativa • Nov 15
APLS: Future Revenue From Kidney Disease Expansion Will Drive Shares Higher
Analysts have modestly lowered their fair value estimate for Apellis Pharmaceuticals from approximately $36.50 to $35.39 per share. This adjustment is due to concerns over slower revenue growth and contracting profit margins following recent company updates.Actualización de narrativa • Oct 31
APLS: Uptake In Rare Kidney Disease Segment Will Drive Future Upside
Analysts have lowered their average price target for Apellis Pharmaceuticals, reducing it by nearly $1 to $36.50. This adjustment reflects moderating revenue growth forecasts and a higher discount rate, although expectations for profit margin have marginally improved.Actualización de narrativa • Sep 27
FDA Label Expansion And SYFOVRE Will Unlock Future Value
Analyst price targets for Apellis Pharmaceuticals have edged lower to $37.47 as positive signals from Syfovre sales and pipeline opportunities are tempered by concerns over limited revenue guidance and commercial ramp uncertainties. Analyst Commentary Bullish analysts cite stabilization in the Geographic Atrophy (GA) market and optimism around the ongoing launches in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).Actualización de narrativa • Aug 27
FDA Label Expansion And SYFOVRE Will Unlock Future Value
The consensus analyst price target for Apellis Pharmaceuticals has risen modestly to $38.56, reflecting improving sentiment from stabilizing Geographic Atrophy market dynamics, continued Syfovre injection growth, and upside potential from Empaveli expansions, despite some concerns over Syfovre sales guidance and a possibly slower Empaveli ramp. Analyst Commentary Bullish analysts point to stabilizing Geographic Atrophy market dynamics and the ongoing launch initiatives in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) as a driver for upward price revisions.Artículo de análisis • Jul 29
Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Nueva narrativa • May 02
SYFOVRE And EMPAVELI Will Broaden Treatment Options Globally
SYFOVRE's strategic expansion and dominant GA market role could significantly drive revenue growth and international market penetration.Seeking Alpha • Mar 05
Apellis Pharmaceuticals: A Mixed Bag
Summary Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complicated tale around this mid-cap, but the company looks set to move to profitability with the funding it has on hand. The analyst firm community is quite mixed on the current prospects around Apellis Pharmaceuticals, however. An analysis around APLS stock follows in the paragraphs below. Read the full article on Seeking AlphaPrevisiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 1,296 | 185 | 49 | 232 | 12 |
| 12/31/2027 | 1,029 | -57 | -7 | 126 | 13 |
| 12/31/2026 | 924 | -102 | 43 | -39 | 5 |
| 3/31/2026 | 1,105 | 133 | 37 | 38 | N/A |
| 12/31/2025 | 1,004 | 22 | 45 | 45 | N/A |
| 9/30/2025 | 1,016 | 45 | 79 | 79 | N/A |
| 6/30/2025 | 755 | -228 | 4 | 4 | N/A |
| 3/31/2025 | 776 | -224 | -8 | -8 | N/A |
| 12/31/2024 | 781 | -198 | -88 | -88 | N/A |
| 9/30/2024 | 715 | -250 | -206 | -205 | N/A |
| 6/30/2024 | 629 | -333 | -409 | -408 | N/A |
| 3/31/2024 | 524 | -417 | -551 | -550 | N/A |
| 12/31/2023 | 397 | -529 | -596 | -595 | N/A |
| 9/30/2023 | 273 | -606 | -639 | -638 | N/A |
| 6/30/2023 | 185 | -657 | -625 | -623 | N/A |
| 3/31/2023 | 106 | -691 | -582 | -580 | N/A |
| 12/31/2022 | 75 | -652 | -515 | -514 | N/A |
| 9/30/2022 | 113 | -634 | -486 | -485 | N/A |
| 6/30/2022 | 97 | -638 | -501 | -500 | N/A |
| 3/31/2022 | 81 | -702 | -522 | -521 | N/A |
| 12/31/2021 | 67 | -746 | -564 | -563 | N/A |
| 9/30/2021 | 256 | -520 | -310 | -309 | N/A |
| 6/30/2021 | 251 | -460 | -245 | -240 | N/A |
| 3/31/2021 | 251 | -360 | -211 | -205 | N/A |
| 12/31/2020 | 251 | -345 | -166 | -160 | N/A |
| 9/30/2020 | 1 | -536 | -389 | -385 | N/A |
| 6/30/2020 | N/A | -470 | -340 | -338 | N/A |
| 3/31/2020 | N/A | -423 | -285 | -284 | N/A |
| 12/31/2019 | N/A | -305 | N/A | -211 | N/A |
| 9/30/2019 | N/A | -228 | N/A | -174 | N/A |
| 6/30/2019 | N/A | -194 | N/A | -153 | N/A |
| 3/31/2019 | N/A | -156 | N/A | -144 | N/A |
| 12/31/2018 | N/A | -128 | N/A | -131 | N/A |
| 9/30/2018 | N/A | -109 | N/A | -102 | N/A |
| 6/30/2018 | N/A | -85 | N/A | -80 | N/A |
| 3/31/2018 | N/A | -64 | N/A | -61 | N/A |
| 12/31/2017 | N/A | -51 | N/A | -47 | N/A |
| 9/30/2017 | N/A | -39 | N/A | -38 | N/A |
| 6/30/2017 | N/A | -35 | N/A | -33 | N/A |
| 3/31/2017 | N/A | -30 | N/A | -28 | N/A |
| 12/31/2016 | N/A | -27 | N/A | -26 | N/A |
| 9/30/2016 | N/A | -29 | N/A | -27 | N/A |
| 6/30/2016 | N/A | -53 | N/A | -24 | N/A |
| 3/31/2016 | N/A | -50 | N/A | -21 | N/A |
| 12/31/2015 | N/A | -47 | N/A | -19 | N/A |
| 9/30/2015 | N/A | -41 | N/A | -14 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (29.8% al año) de APLS es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (29.8% al año) de APLS crezcan más rápidamente que el mercado US (16.8% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de APLS crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (8.6% al año) de APLS crezcan más despacio que el mercado de US (11.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 8.6% al año) de APLS crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de APLS sea muy elevada dentro de 3 años (55.1%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/16 15:23 |
| Precio de las acciones al final del día | 2026/05/13 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Apellis Pharmaceuticals, Inc. está cubierta por 28 analistas. 13 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Michael Ulz | Baird |
| Colleen Kusy | Baird |
| Eliana Merle | Barclays |